Australia markets close in 1 hour 54 minutes

Opthea Limited (OPT.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.36500.0000 (0.00%)
As of 01:55PM AEST. Market open.
Full screen
Previous close0.3650
Open0.3650
Bid0.3600 x 1566800
Ask0.3650 x 380500
Day's range0.3650 - 0.3750
52-week range0.3125 - 0.8150
Volume1,742,801
Avg. volume972,767
Market cap321.461M
Beta (5Y monthly)0.70
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date11 Oct 2004
1y target estN/A
  • GlobeNewswire

    Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)

    Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m1) will open on 19 June 2024 and close at 5:00 pm (Melbourne time) on 10 July 2024 MELBOURNE, Australia and PRINCETON, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD),

  • GlobeNewswire

    Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)

    Financing extends Opthea’s cash runway through Phase 3 topline data readout for both pivotal trials of sozinibercept in wet AMD Phase 3 topline data readout accelerated for COAST to early Q2 calendar year 2025, and anticipated for ShORe in mid-calendar year 2025 MELBOURNE, Australia and PRINCETON, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and pr

  • GlobeNewswire

    Opthea To Present at Clinical Trials at the Summit Meeting

    MELBOURNE, Australia and PRINCETON, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that the Company will make several presentations at the Clinical Trials at the Summit (CTS) Meeting being held in Park City, Utah on June 8, 2024. Frederic Guerar